UMA
14.12.2021 11:02:09 CET | Business Wire | Press release
Jabra and UMA have partnered to deliver innovative video conferencing and meeting room solutions, enabling Jabra devices to be managed seamlessly from one place on the UMA dashboard with real-time analytics. With Jabra PanaCast intelligent video conferencing cameras, users can manage meeting room occupancy levels and control room occupancy levels from a desktop, smartphone or meeting room display panel to optimise the use of office space.
The Jabra PanaCast and PanaCast 50’s unique 180-degree field-of-view covers the whole room and generates anonymous room occupancy data. This feeds real-time information into the UMA dashboard, providing insights and analytics. UMA automatically makes a meeting room available to book in the event of a no-show. Rooms can also be auto-booked by simply walking in.
With the shift towards hybrid-working, companies are reviewing their technology investments and office space-utilisation. UMA enables users to manage meeting-room and desk utilisation and device management of audio-visual devices, all from a single pane of glass. Organisations are now able to optimise their facilities and technology infrastructure to create an efficient and safe workplace, compliant with Covid Winter-Plan guidelines.
The combined value-proposition of UMA and Jabra allows customers to realise an improved return on their technology investments through business intelligence and simpler mechanisms to support and maintain their meeting room technology. Users can check Jabra device status, remotely diagnose and fix issues, and push software updates.
Nigel Dunn, Managing Director, EMEA North at Jabra says, “We are thrilled to be teaming up with UMA to deliver a new standard in meeting room solutions for hybrid working. Jabra PanaCast’s data-driven insights and analytics gives a real-time view of how the workplace is being used, enabling companies to improve efficiency and maximise their real estate. It’s now time to start thinking about future-proofing offices and taking conferencing and the meeting booking experience to the next level.”
Nathan Rogers, Head of Channel, UMA says, “I’m looking forward to continuing to build a strong partnership with Jabra. The UMA and Jabra integration will deliver meaningful insights to businesses ensuring they understand how their real estate is being used. UMA delivers a simplified user experience to enable the booking of meeting spaces, and when partnered with the Jabra PanaCast the business has enhanced analytical data at their fingertips. Jabra’s audio experience and smart UC technology working in coalition with our Workplace Software will deliver a game changing advantage to users.”
Working in partnership with our mutual UK and European distributors means the reseller and Integrator customers will get a cohesive approach.”
The Jabra PanaCast is supported on UMA’s platform today, with PanaCast 50 to follow in early 2022.
For more information, please visit: https://www.jabra.co.uk/Business/for-your-platform/uma
About Jabra
Jabra is a world leading brand in audio, video, and collaboration solutions – engineered to empower consumers and businesses. Proudly part of the GN Group, we are committed to letting people hear more, do more, and be more than they ever thought possible. Jabra engineering excellence leads the way, building on 150 years of pioneering work within the GN Group.
This allows us to create integrated tools for contact centres, offices, and collaboration that help professionals work more productively from anywhere; and true wireless headphones and earbuds that let consumers better enjoy calls, music, and media. The GN Group, founded in 1869, operates in 100 countries and delivers innovation, reliability, and ease of use. GN employs 6,500 people and in 2020 reported annual revenue of DKK 13.4bn. The Jabra brand accounts for approx. DKK 8.7bn and employs 1,900 people. GN makes life sound better and is Nasdaq Copenhagen listed. www.jabra.com
About UMA
UMA is an innovative workplace software-as-a-service platform, connecting internet-of-things, audio, video, and collaboration technology and digitising the workplace environment.
Driven by a passion to improve technology user experiences in the workplace UMA enables you to book and manage resources and optimise space and environmental conditions, adapting to the changing needs of the workforce.
UMA was founded in Halifax, Yorkshire, UK and delivers solutions to enterprise and SME customers from all industry verticals across the world.
Find out more and get started with a free trial of UMA at www.askuma.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005063/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
